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Abstract Background. Multi-drug resistant bacteria are
a growing concern in healthcare. Daptomycin is being used
with increasing frequency in the treatment of
vancomycin-resistant
enterococci
(VRE)
and
methicillin-resistant Staphylococcus aureus (MRSA)
bacteremias in hemodialysis (HD) patients. Thrice-weekly
dosing of daptomycin in this population would allow for
coordination of dosing with common outpatient HD
schedules. The aim of this study is to determine if
thrice-weekly dosing of daptomycin is equivalent to dosing
every 48 hours in patients receiving chronic intermittent
hemodialysis. Equivalence will be assessed with regard to
microbiological cure, clinical cure, hospital length of stay,
and mortality. Methods. All patients with positive blood
cultures who received at least one dose of daptomycin
between January 1st 2009 and December 31st 2010 at
Indiana University Health Methodist and University
Hospitals were identified. Adult patients with end-stage
renal disease on a stable thrice-weekly hemodialysis
regimen, confirmed VRE or MRSA bacteremia, and at least
three doses of inpatient daptomycin therapy were enrolled
in the study. Results. Twelve patients met criteria for
inclusion in this study. Nine received daptomycin every 48
hours for the treatment of bacteremia, and three received
daptomycin thrice-weekly after dialysis. There was no
difference in time to clearance of blood cultures between
the Q48H and thrice-weekly groups (2.11±2.15 days vs.
4.33±4.16 days; p=0.241).Length of hospital stay was not
statistically significantly different between the two groups
(22.8 days vs. 14.9 days; p=0.065).Conclusions.
Thrice-weekly dosing of daptomycin may be effective for
the treatment of bacteremia in hemodialysis patients.
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1. Introduction
Multi-drug resistant bacteria are a growing concern in
healthcare. Two increasingly problematic gram-positive
pathogens are methicillin-resistant Staphylococcus aureus
(MRSA) and vancomycin-resistant enterococci (VRE).
Greater than 50% of S. aureus isolates are considered
methicillin-resistant, and vancomycin remains the first-line
treatment for MRSA infections.[1-3] The Clinical
Laboratory and Standards Institute (CLSI) and European
Committee on Antimicrobial Susceptibility Testing
(EUCAST) define strains with a minimum inhibitory
concentration (MIC) of ≤ 2mCg/mL as susceptible to
vancomycin, meaning there is a high likelihood of
therapeutic success if this agent is used. However, available
literature indicates that higher MICs (i.e. ≥ 1.5mCg/mL) are
associated with increased risk of treatment failure in
bacteremia.[2,3] Thus, patients with infections due to MRSA
with elevated vancomycin MICs may be candidates for
treatment with alternative antibiotics, such as daptomycin.
Approximately 95% of VRE strains identified in the
United States are Enterococcus faecium. Isolates of
Enterococcus with MICs of > 4mCg/mL have a high
likelihood of treatment failure and are thus considered
resistant to vancomycin. These organisms also possess
intrinsic resistance to many other antibiotic classes, and
treatment
options
are
limited
to
linezolid,
quinupristin/dalfopristin, and daptomycin.[4]
General risk factors for MRSA and VRE bacteremia
include previous exposure to broad-spectrum antibiotics,
prolonged hospitalization (>5 days), admission to the
intensive care unit, and the presence of invasive devices.[5,6]
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In addition to frequently possessing these risk factors,
hemodialysis (HD) patients are often immunocompromised
and repeated exposure to healthcare settings increases their
likelihood of developing MRSA or VRE bacteremia
requiring treatment.
According to the package insert, the recommended dosing
of daptomycin for the treatment of bacteremia in patients
receiving HD is 6mg/kg IV every 48 hours.[7] In contrast,
the Infectious Disease Society of America recommends
administering 6mg/kg IV after each dialysis session.[8] A
growing body of pharmacokinetic data exists to support
post-dialysis dosing, but clinical evidence is limited. If
effective, thrice-weekly post-dialysis dosing could provide
significant benefits including completion of therapy in the
outpatient setting, improved convenience for both the patient
and the healthcare provider, and significant cost savings.
The objective of this study was to assess clinical outcomes
in chronic hemodialysis patients with MRSA or VRE
bacteremia treated with thrice-weekly compared to Q48H
daptomycin and to determine if these two dosing schedules
may be equivalent in this population.

blood culture were used to assess microbiologic cure.

2. Subjects and Methods

Twelve patients met inclusion criteria for this study. Nine
subjects received daptomycin every 48 hours for treatment of
bacteremia and three received daptomycin thrice-weekly
after dialysis. Patient demographic characteristics are shown
in Table 1.Of the twelve subjects, nine had VRE, two had
MRSA, and one had concomitant VRE and MRSA. The
MICs of the isolates to vancomycin and daptomycin are
shown in Figures 1 and 2, respectively. Of note, two MRSA
isolates had MIC ≤ 1 mg/dL to vancomycin and thus may
have been treated effectively with vancomycin. However,
one isolate was identified in an individual with a documented
vancomycin allergy, and the other was identified
concomitantly with VRE. The maximum MIC to daptomycin
in the identified organisms was 3 mg/dL.
The mean dose of daptomycin received was 7.8 ± 1.4
mg/kg (based on actual body weight) for the Q48H group,
compared to 7.2 ± 1.2 mg/kg for the thrice-weekly group
(p=0.517).Doses ranged from 5.8 to 10.6 mg/kg in the Q48H
group and from 5.9 to 8.3 mg/kg in the thrice-weekly group.
All patients achieved microbiological cure, defined as the
clearance of blood cultures prior to hospital discharge. There
was no difference in time from initiation of daptomycin
therapy to clearance of blood cultures between the Q48H and
thrice-weekly groups (2.11±2.15 days vs. 4.33±4.16 days;
p=0.241).All study subjects demonstrated clearance of
cultures within five days of initiating daptomycin therapy,
with the exception of the single subject infected with both
MRSA and VRE who was treated for 9 days before cultures
were completely negative (Figure 3). There was no
relationship between time to culture clearance and
daptomycin dose.
No patients were febrile (Tmax ≥ 38.3°C) upon initiation
of daptomycin, and only three patients in the Q48H group

2.1. Selection Criteria
All patients who received at least one dose of daptomycin
between January 1st 2009 and December 31st 2010 at
Methodist and Indiana University Hospitals were identified.
Subjects were included if they were at least 18 years old, had
end-stage renal disease on a stable thrice-weekly HD
regimen, had an MRSA or VRE bacteremia confirmed by at
least one positive blood culture, received three or more doses
of daptomycin on one of the study schedules, and had at least
three recorded white blood cell (WBC) counts. Subjects who
had a polymicrobial (gram-positive and gram-negative)
bacteremia or clearly identifiable concomitant MRSA
pneumonia were excluded from the study. Subjects were also
excluded if they had received daptomycin within 30 days
prior to admission or had any deviation from the study
regimen. The study was reviewed and approved by the
Indiana University-Purdue University Indianapolis/Clarian
Institutional Review Board.
2.2. Data Collection
Data were obtained through a retrospective review of
electronic medical records. Demographic information
included age, gender, height, weight, and comorbidities.
Length of hospital stay, in-hospital mortality, identity of the
isolate (MRSA or VRE) and its susceptibility (MIC) to
vancomycin and daptomycin were also recorded. Clinical
indicators of infection, including daily maximum
temperature (Tmax) and WBC count, were tracked. Date of
first positive blood culture and first completely negative

2.3. Outcome Measures
The primary outcome of this study was occurrence of
microbiological cure (clearance of blood cultures) prior to
discharge. Secondary outcomes included occurrence of
clinical cure (Tmax < 38.3°C, WBC < 11.5 cells/mm3) prior
to discharge, length of hospital stay, and in-hospital
mortality.
2.4. Statistical Analysis.
A Kolmogorov-Smirnov test was used to determine the
normality of distribution of the data. Fisher’s exact and
chi-square tests were used to compare demographic
characteristics between cohorts, and Student’s t-test was
used to compare continuous data. A p-value of less than or
equal to 0.05 was considered to indicate a statistically
significant difference.

3. Results
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had a clinically significant WBC count (defined as > 11.5
cells/mm3 at the study institutions) on initiation of
daptomycin. Length of hospital stay was not significantly
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different between the two groups, however a trend toward
shorter length of stay was noted in the thrice-weekly group
(22.8 days vs. 14.9 days; p=0.065).

Table 1. Subject Demographic Characteristics
Characteristic

Value
Thrice-Weekly

Q48H

Age (years)*

55 (32 – 57)

58 (27 – 64)

Female

0 (0)

5 (55.6)

Male

3 (100)

4 (44.4)

Actual Body Weight (kg)*

81 (60 – 135)

64 (55 – 88)

Dose (mg/kg ABW)*

7.4 (5.9 – 8.3)

7.9 (5.8 – 10.6)

Length of Stay*

14.9 (7.8 – 17.9)

22.8 (5.9 – 75)

In-hospital mortality#

0 (0)

0 (0)

*Median (Range), #Number (%)

Figure 1. Minimum Inhibitory Concentrations (MICs) of Study Isolates to Vancomycin.

4

A Retrospective Comparison of Daptomycin Thrice-Weekly versus Q48H Dosing in Hemodialysis
Patients with Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant
Staphylococcus aureus (MRSA) Bacteremia

Figure 2. Minimum Inhibitory Concentrations (MICs) of Study Isolates to Daptomycin.

Figure 3. Time to Clearance of Blood Cultures.

4. Discussion
Daptomycin is being used with increasing frequency in the
treatment of MRSA and VRE bacteremia in HD patients.
Thrice-weekly dosing would provide significant cost savings
to the healthcare system. Perhaps more importantly,
thrice-weekly dosing of daptomycin would be more
convenient for both patients and healthcare providers when
treatment can be completed on an outpatient basis. The
combination of these benefits has the potential to drastically
increase adherence to prescribed antibiotic regimens.
However, these potential benefits are of no value if
thrice-weekly dosing of daptomycin proves ineffective.
Further studies to confirm that thrice-weekly dosing is
non-inferior to Q48H dosing for the treatment of bacteremia
are thus justified.
Salama and colleagues published a pharmacokinetic study

in which six non-bacteremic HD patients were given a single
6mg/kg IV dose of daptomycin following an HD session.[9]
Serial blood samples were collected for 44 hours after the
dose and throughout the subsequent session. This data was
then used to model trough serum concentrations at 44 and 68
hours after 6mg/kg, 8mg/kg, and 10mg/kg post-HD doses.
Based on their results, the authors predicted that HD patients
would maintain daptomycin concentrations sufficiently
above the MIC of S. aureus (≤ 1mCg/mL) and E. faecium (≤
4mCg/mL) at 68 hours after a 6, 8, or 10 mg/kg dose. This
suggests that HD patients should be able to receive
thrice-weekly post-dialysis doses of daptomycin rather than
Q48H, allowing for coordination of dosing with common
outpatient
HD
schedules
(e.g.,
every
Monday/Wednesday/Friday).
Patel and colleagues used pharmacokinetic modeling and
Monte Carlo simulations in effort to characterize daptomycin
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pharmacokinetics in HD patients and identify an ideal dosing
regimen for HD patients receiving daptomycin therapy.[10]
Blood samples were collected from twelve non-bacteremic
HD patients over three consecutive days during the patient’s
regular dialysis routine. A single dose of daptomycin 6mg/kg
IV was administered to each patient on study day 1 after
hemodialysis. The mathematic models employed in this
study demonstrated that administering daptomycin during or
immediately following HD results in pharmacokinetic values
similar to those seen in studies of non-dialysis patients.
Based on their results, the authors suggest that it may be
appropriate to administer a 50% larger daptomycin dose
prior to a two day dialysis holiday (i.e. with Friday dialysis in
patients receiving HD every Monday/Wednesday/Friday or
with Saturday dialysis in patients receiving HD every
Tuesday/Thursday/Saturday).
In
effort
to
develop
a
single,
pharmacokinetically-optimized daptomycin dosing regimen
for the dialysis population, data from Salama and Patel was
pooled along with data from a multiple-dose kinetic study
conducted by Benziger et al.[11,12] Results of the combined
analysis support the recommendation that administration of
standard daptomycin doses during or post-HD on dialysis
days, with a 50% dose increase prior to the 72-hour
interdialytic period will achieve daptomycin concentrations
that most closely resemble exposure to Q24H dosing in
non-dialysis patients.
While results of these pharmacokinetic studies suggest a
high likelihood of success when daptomycin is administered
thrice-weekly with dialysis, clinical evidence is still lacking.
The current study found no statistically significant difference
in microbiological cure between patients who received
daptomycin thrice-weekly after dialysis and those who
received the antibiotic on a Q48H regimen. It should be
noted that the average daptomycin doses used in these
patients were higher than currently recommended (7.7 mg/kg
vs. 6mg/kg).
In designing this study, the intent was to assess the time to
clinical cure using common indicators of infection:
temperature and WBC counts. Despite having documented
bacteremia, none of the subjects observed were febrile upon
initiation of daptomycin. One possible explanation for this is
that hemodialysis alters body temperature regulation, and
HD patients may have an altered fever response in the setting
of infection.[13] Similarly, only 3 patients in the Q48H
group had elevated WBC counts above 11.5 cells/mm3 at the
initiation of daptomycin, possibly due to an overall
immunocompromised state and inability to mount an
appropriate response to infection. This interesting
observation suggests that we may not be able to rely on
generally accepted clinical indicators to identify infection or
to assess clinical status and cure.
This study has several limitations which must be noted.
First of all, the practice of administering daptomycin
thrice-weekly after dialysis was a somewhat novel concept at
the beginning of the study period. This is believed to be a
large contributing factor to the small study population
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identified. The retrospective nature of the study inherently
eliminates the opportunity to establish a study protocol. Thus,
blood cultures were checked and re-checked at the discretion
of the provider, and there were no guidelines for
standardized dosing of daptomycin. Finally, as discussed
previously, the effects of hemodialysis and overall
immunocompromised status of patients in this study
population make it challenging to assess the impact of
treatment on indicators of clinical cure.
The treatment of multi-drug resistant bacteremia in the
end-stage renal disease population is often multifactorial and
complicated by comorbid conditions and unconventional
clinical responses to therapy. While the results of this study
cannot establish noninferiority of thrice-weekly daptomycin
compared to Q48H dosing, they do provide evidence to
support further research.

5. Conclusion
Other studies have aimed to better characterize the
pharmacokinetics of daptomycin in hemodialysis patients
and determine the most appropriate dosing regimen in this
population. To the best of our knowledge, this is the first
attempt to compare clinical outcomes in patients treated with
thrice-weekly, post-dialysis daptomycin to those of patients
treated with every 48 hour dosing. Although our study
population was small, the results suggest that the use of more
convenient and less costly thrice-weekly dosing may be an
appropriate approach for the treatment of bacteremia in
patients on hemodialysis.

Conflict of Interest Statement
The authors have had no involvements that might raise the
question of bias in the work reported or in the conclusions,
implications, or opinions stated. The results of this study
were presented at the 2011 Great Lakes Pharmacy Resident
Conference (continuing education presentation) and the
2011 American College of Clinical Pharmacy Annual
Meeting (poster).

REFERENCES
[1]

Klein E, Smith DL, Laxminarayan R. Hospitalizations and
deaths caused by methicillin-resistant Staphylococcus aureus,
United States, 1999-2005. Emerg Infect Dis. Vol. 13, No. 12,
1840-1846, 2007.

[2]

Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship
of MIC and bactericidal activity to efficacy of vancomycin for
treatment of methicillin-resistant Staphylococcus aureus
bacteremia. J Clin Microbiol. Vol. 42, No. 6, 2398-2402,
2004.

[3]

Lodise TP, Graves J, Evans A, et al. Relationship between
vancomycin MIC and failure among patients with

6

methicillin-resistant Staphylococcus aureus bacteremia
treated with vancomycin. Antimicrob Agents Chemother. Vol.
52, No. 9, 3315-3320, 2008.

[9]

[4]

Rice LB. Emergence of vancomycin-resistant enterococci.
Emerg Infect Dis. Vol. 7, No. 2, 183-187, 2001.

[5]

Noskin GA. Vancomycin-resistant enterococci: clinical,
microbiologic, and epidemiologic features. J Lab Clin Med.
Vol. 130, No. 1, 14, 1997.

[10] Patel N, Cardone K, Grabe DW, et al. Use of pharmacokinetic
and pharmacodynamics principles to determine optimal
administration of daptomycin in patients receiving
standardized thrice-weekly hemodialysis. Antimicrob Agents
Chemother. Vol. 55, No. 4, 1677-1683, 2011.

[6]

Doebbling BN. The epidemiology of methicillin-resistant
Staphylococcus aureus colonization and infection. J
Chemother. Vol. 7, No. 3 (suppl), 99-103, 1995.

[7]

Cubicin (daptomycin) [package insert]. Lexington, MA:
Cubist Pharmaceuticals, Inc.; May 2006.

[8]

Mermel LA, Allon M, Bouza E, et al. Clinical practice
guidelines for the diagnosis and management of intravascular
catheter-related infection: 2009 update by the Infectious
Diseases Society of America. Clin Infect Dis. Vol. 49, 1-45,
2009.

Salama NN, Segal JH, Churchwell MD, et al. Single-dose
daptomycin pharmacokinetics in chronic hemodialysis
patients. Nephrol Dial Transplant. Vol. 25, 1279-1284, 2010.

[11] Benziger DP, Pertel PE, Donovan J, et al. Pharmacokinetics
and safety of multiple doses of daptomycin 6 mg/kg in
noninfected adults undergoing hemodialysis or continuous
ambulatory peritoneal dialysis. Clin Nephrol. Vol. 75, 63-69,
2011.
[12] Butterfield JM, Mueller BA, Patel N, et al. Daptomycin
pharmacokinetics and pharmacodynamics in a pooled sample
of patients receiving thrice-weekly hemodialysis. Antimicrob
Agents Chemother. Vol. 57, No. 2, 864-872, 2013.
[13] Matheson R, Sawatzky JV. Altered fever response in end
stage renal disease: implications for critical care nurses.
Dynamics. Vol. 18, No. 4, 14-18, 2007.

